Eli Lilly on Tuesday reported fourth-quarter revenue and adjusted earnings that topped expectations on the strong launch of its new weight loss drug, Zepbound, and higher prices for its blockbuster d… [+4697 chars]Read More
Eli Lilly results blow past estimates on strong Zepbound launch surging Mounjaro revenue CNBC
